COPPELL, TX, Jul 07, 2005 (MARKET WIRE via COMTEX) -- Mannatech, Incorporated (MTEX) Mannatech Inc. announced today the results of an independent scientific study recently concluded in Australia on the company's antioxidant product, Ambrotose AO(R). A dose-response study of the antioxidant effects of Ambrotose AO(R) in 22 healthy subjects, 13 smokers and 9 non-smokers, demonstrated a significant increase in the antioxidant levels in the blood (serum ORAC). The increase was observed between a dose of zero to 4 capsules per day (p = 0.040), equating to a 36.6% improvement.
This research was sponsored by Mannatech, Inc., and was independently conducted by the Australian Centre for Complementary Medicine Education and Research (ACCMER), a joint venture of two Australian universities, the University of Queensland and Southern Cross University.
Mannatech Chairman and CEO Sam Caster said, "This study further validates the positive impact on biomarkers through the oral intake of antioxidant and glyconutrient-based supplements."
A follow-up study is planned based on these results, which will use a double-blind, placebo-controlled, randomized design to further assess the efficacy of Ambrotose AO(R) on 60 healthy individuals.
Released in 2003, Ambrotose AO(R) is a revolutionary product that gains its advantage from a synergistic, proprietary formula, AO Blend (patent-pending). The proprietary anti-oxidant formula is combined with a base of Ambrotose(R), Mannatech's patent-pending glyconutrient complex, designed to support health and assist in the fight against harmful free radicals caused by oxidative stress.
Based in Coppell, Texas, Mannatech, Incorporated is a wellness solutions provider that develops innovative, high-quality, proprietary nutritional supplements, topical products and weight management products, which are sold through a global network marketing system throughout the United States and the international markets of Canada, Australia, the United Kingdom, Japan, New Zealand, South Korea and Taiwan.
The Australian Centre for Complementary Medicine Education & Research (ACCMER) is a joint venture between the Faculty of Health Sciences, University of Queensland and the School of Natural and Complementary Medicine, Southern Cross University. Both Universities have joined together to establish a unique collaborative research and education centre, with the objective of providing an independent reference point built on substantial strengths in research, innovation and teaching. ACCMER has built a reputation as a leading provider of scientific research services such as Clinical Trials, Surveys and Analysis, Literature Reviews, Laboratory Science and Social Research.
**The statements in this release have not been evaluated by the Food and Drug Administration. This product is not intended to treat, cure, of prevent any disease.**
Please Note: This release contains "forward-looking statements" within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements generally can be identified by use of phrases or terminology such as "may," "believes," "estimates," "projects," "well positioned," "feels," and "plans" or other similar words or the negative of such terminology. Similarly, descriptions of Mannatech's objectives, strategies, plans, goals or targets contained herein are also considered forward-looking statements. Mannatech believes this release should be read in conjunction with all of its filings with the Securities and Exchange Commission and cautions its readers that these forward-looking statements are subject to certain events, risks, uncertainties, and other factors. Some of these factors include, among others, Mannatech's inability to attract and retain associates and members, increases in competition, litigation, regulatory changes, and its planned growth into new international markets. Although Mannatech believes that its expectations, statements, and assumptions reflected in these forward-looking statements are reasonable, it cautions its readers to always consider all of the risk factors and any other cautionary statements carefully in evaluating each forward-looking statement in this release, as well as those set forth in its latest Annual Report on Form 10-K, and other filings filed with the Securities and Exchange Commission, including its current reports on Form 8-K. All of the forward-looking statements contained herein speak only as of the date of this release.